Explore

Trendline Trendline
Madrigal Pharmaceuticals Acquires siRNA Asset for MASH in $1 Billion Deal with Arrowhead

Madrigal Pharmaceuticals Acquires siRNA Asset for MASH in $1 Billion Deal with Arrowhead

Madrigal Pharmaceuticals Acquires siRNA Asset for MASH in $1 Billion Deal with Arrowhead
Trendline Trendline
Mapi Pharma Plans U.S. Aseptic Manufacturing Facility to Meet Growing Demand for Injectables

Mapi Pharma Plans U.S. Aseptic Manufacturing Facility to Meet Growing Demand for Injectables

Mapi Pharma Plans U.S. Aseptic Manufacturing Facility to Meet Growing Demand for Injectables
Trendline Trendline
Mirum Pharmaceuticals Achieves Key Milestone in PSC Treatment with Volixibat

Mirum Pharmaceuticals Achieves Key Milestone in PSC Treatment with Volixibat

Mirum Pharmaceuticals Achieves Key Milestone in PSC Treatment with Volixibat
Trendline Trendline
Takeda's TAK-881 Shows Promising Results in Phase 2/3 Trial for Primary Immunodeficiency Disease

Takeda's TAK-881 Shows Promising Results in Phase 2/3 Trial for Primary Immunodeficiency Disease

Takeda's TAK-881 Shows Promising Results in Phase 2/3 Trial for Primary Immunodeficiency Disease
Trendline Trendline
Connecticut Biopharmaceutical Company Reports Promising Results for Experimental Hair Loss Pill

Connecticut Biopharmaceutical Company Reports Promising Results for Experimental Hair Loss Pill

Connecticut Biopharmaceutical Company Reports Promising Results for Experimental Hair Loss Pill
Trendline Trendline
IDEAYA Biosciences Reports Positive Results and Business Updates for Q1 2026

IDEAYA Biosciences Reports Positive Results and Business Updates for Q1 2026

IDEAYA Biosciences Reports Positive Results and Business Updates for Q1 2026
Trendline Trendline
Alnylam Pharmaceuticals to Showcase Vutrisiran Data at Heart Failure 2026

Alnylam Pharmaceuticals to Showcase Vutrisiran Data at Heart Failure 2026

Alnylam Pharmaceuticals to Showcase Vutrisiran Data at Heart Failure 2026
Trendline Trendline
UCB Acquires Candid Therapeutics for $2 Billion to Expand T-Cell Engager Therapies

UCB Acquires Candid Therapeutics for $2 Billion to Expand T-Cell Engager Therapies

UCB Acquires Candid Therapeutics for $2 Billion to Expand T-Cell Engager Therapies
Trendline Trendline
Mapi Pharma Plans U.S. Aseptic Manufacturing Facility to Meet Rising Demand

Mapi Pharma Plans U.S. Aseptic Manufacturing Facility to Meet Rising Demand

Mapi Pharma Plans U.S. Aseptic Manufacturing Facility to Meet Rising Demand
Trendline Trendline
GRIN Therapeutics Expands Phase 3 Beeline Study for GRIN-NDD in Europe

GRIN Therapeutics Expands Phase 3 Beeline Study for GRIN-NDD in Europe

GRIN Therapeutics Expands Phase 3 Beeline Study for GRIN-NDD in Europe
Trendline Trendline
Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Clinical Expansion

Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Clinical Expansion

Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Clinical Expansion
Reuters Reuters
US FDA declines to approve AbbVie's wrinkle treatment due to manufacturing concerns (April 23)

US FDA declines to approve AbbVie's wrinkle treatment due to manufacturing concerns (April 23)

(Corrects headline to say the FDA "declines" to approve the treatment and not "rejects". Also corrects first bullet to say the treatment starts to work, not wears off, as early as 8 hours and removes comparison to Botox) By Padmanabhan Ananthan April 23 (Reuters) - AbbVie said on Thursday the U.S.